These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 27913493)
1. Novel agents in follicular lymphoma: choosing the best target. Sehn LH Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):284-292. PubMed ID: 27913493 [TBL] [Abstract][Full Text] [Related]
2. Follicular lymphoma: The long and winding road leading to your cure? Gordon MJ; Smith MR; Nastoupil LJ Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982 [TBL] [Abstract][Full Text] [Related]
3. The role of obinutuzumab in the management of follicular lymphoma. O'Nions J; Townsend W Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821 [TBL] [Abstract][Full Text] [Related]
5. Transformation of follicular lymphoma - Why does it happen and can it be prevented? Link BK Best Pract Res Clin Haematol; 2018 Mar; 31(1):49-56. PubMed ID: 29452666 [TBL] [Abstract][Full Text] [Related]
6. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy? Fowler N Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of microenvironment in follicular lymphoma. Nowakowski GS; Ansell SM Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):169-73. PubMed ID: 25696851 [TBL] [Abstract][Full Text] [Related]
8. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. Pon JR; Marra MA Blood; 2016 Jan; 127(2):181-6. PubMed ID: 26447189 [TBL] [Abstract][Full Text] [Related]
9. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP. Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848 [TBL] [Abstract][Full Text] [Related]
15. Novel agents for relapsed and refractory follicular lymphoma. Cheah CY; Fowler NH Best Pract Res Clin Haematol; 2018 Mar; 31(1):41-48. PubMed ID: 29452665 [TBL] [Abstract][Full Text] [Related]
16. An analysis of genetic targets for guiding clinical management of follicular lymphoma. Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA Expert Rev Hematol; 2020 Dec; 13(12):1361-1372. PubMed ID: 33176509 [No Abstract] [Full Text] [Related]
17. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699 [TBL] [Abstract][Full Text] [Related]
19. Treatment of follicular lymphoma: current status. Tilly H; Zelenetz A Leuk Lymphoma; 2008; 49 Suppl 1():7-17. PubMed ID: 18821428 [TBL] [Abstract][Full Text] [Related]
20. Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model. Andjelić B; Todorović-Balint M; Antić D; Bila J; Djurašinović V; Mihaljević B Vojnosanit Pregl; 2015 Jan; 72(1):26-32. PubMed ID: 26043587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]